Literature DB >> 1347805

Induction of thromboses within renal grafts by high-dose prophylactic OKT3.

D Abramowicz1, O Pradier, A Marchant, S Florquin, L De Pauw, P Vereerstraeten, P Kinnaert, J L Vanherweghem, M Goldman.   

Abstract

Among 93 consecutive kidney-transplant patients who received prophylactic OKT3 10 mg/day for 2 weeks, 9 had intragraft thromboses within 2 weeks of transplantation. The thromboses were in graft artery in 1 patient and veins in 3. The other 5 had thromboses in glomerular capillaries and thrombotic microangiopathy similar to that of haemolytic-uraemic syndrome. All attempted treatments failed, and the 9 grafts had to be removed. The finding that plasma concentrations of prothrombin fragment 1 and 2 were higher 4 h after the first OKT3 dose in OKT3 recipients than in transplant patients who received other prophylaxis (mean 5.88 [SEM 0.76] vs 2.25 [0.59] nmol/l, p less than 0.01) confirms that OKT3 has procoagulant effects in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347805     DOI: 10.1016/0140-6736(92)91897-h

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

Review 3.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

4.  Hemolytic uremic syndrome after renal transplantation.

Authors:  G V Vergoulas
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

Review 5.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

Review 6.  Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

7.  In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.

Authors:  K J Parlevliet; I J ten Berge; S L Yong; J Surachno; J M Wilmink; P T Schellekens
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 8.  Post-bone marrow transplant thrombotic microangiopathy.

Authors:  F Obut; V Kasinath; R Abdi
Journal:  Bone Marrow Transplant       Date:  2016-03-14       Impact factor: 5.483

Review 9.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

10.  Dose kidney transplant nephrectomy stop disease progression in plasma exchange resistant post transplant hemolytic uremic syndrome? A case report.

Authors:  Farzaneh Sharifipour; Abbasali Zeraati; Seyed Seifollah Beladi Mousavi; Fatemeh Hayati; Mohsen Tavazoe; Marzieh Beladi Mousavi
Journal:  J Nephropathol       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.